Zinc and cardiovascular disease

Nutrition

Volumn 26, Issue 11-12, 2010, Pages 1050-1057

  Little, Peter J ^a,b   Bhattacharya, Runa ^c   Moreyra, Abel E ^c   Korichneva, Irina L ^c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PYRITHIONE ZINC; THIAZIDE DIURETIC AGENT; ZINC; ZINC TRANSPORTER;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; DRUG MECHANISM; HEART ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPERFUSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ZINC BLOOD LEVEL; ZINC DEFICIENCY; ZINC METABOLISM;

ANIMALS; ARTERIOSCLEROSIS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETIC CARDIOMYOPATHIES; HEART FAILURE; HOMEOSTASIS; HUMANS; SIGNAL TRANSDUCTION; ZINC;

EID: 77957778826     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.03.007     Document Type: Review

References (73)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Glass C.K., Witztum J.L., Atherosclerosis The road ahead. Cell 2001, 104:503-516.
4. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
5. Haffner S.M., D'Agostino R., Mykkanen L., Tracy R., Howard B., Rewers M., et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999, 22:562-568.
6. Vrecer M., Turk S., Drinovec J., Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003, 41:567-577.
7. Kuller L.H. Nutrition, lipids, and cardiovascular disease. Nutr Rev 2006, 64:S15-S26.
8. Dunstan D.W., Mori T.A., Puddey I.B., Beilin L.J., Burke V., Morton A.R., Stanton K.G. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb Haemost 1999, 81:367-372.
9. Dunstan D.W., Salmon J., Healy G.N., Shaw J.E., Jolley D., Zimmet P.Z., Owen N. Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes. Diabetes Care 2007, 30:516-522.
10. Swaminathan S., Fonseca V.A., Alam M.G., Shah S.V. The role of iron in diabetes and its complications. Diabetes Care 2007, 30:1926-1933.
11. Shi Z.M., Hu X.S., Yuan B.J., Gibson R., Dai Y., Garg M. Association between magnesium: iron intake ratio and diabetes in Chinese adults in Jiangsu Province. Diabet Med 2008, 25:1164-1170.
12. Lindgren C.M., McCarthy M.I. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab 2008, 4:156-163.
13. Brayer K.J., Segal D.J. Keep your fingers off my DNA: protein-protein interactions mediated by C2H2 zinc finger domains. Cell Biochem Biophys 2008, 50:111-131.
14. Karagulova G., Yue Y., Moreyra A., Boutjdir M., Korichneva I. Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. J Pharmacol Exp Ther 2007, 321:517-525.
15. Hettiarachchi M., Liyanage C., Wickremasinghe R., Hilmers D.C., Abrams S.A. The efficacy of micronutrient supplementation in reducing the prevalence of anaemia and deficiencies of zinc and iron among adolescents in Sri Lanka. Eur J Clin Nutr 2008, 62:856-865.
16. Griffin I.J., Kim S.C., Hicks P.D., Liang L.K., Abrams S.A. Zinc metabolism in adolescents with Crohn's disease. Pediatr Res 2004, 56:235-239.
17. Abrams S.A. Assessing mineral metabolism in children using stable isotopes. Pediatr Blood Cancer 2008, 50:438-441.
18. Coudray C., Charlon V., de Leiris J., Favier A. Effect of zinc deficiency on lipid peroxidation status and infarct size in rat hearts. Int J Cardiol 1993, 41:109-113.
19. Powell S.R., Aiuto L., Hall D., Tortolani A.J. Zinc supplementation enhances the effectiveness of St. Thomas' Hospital No. 2 cardioplegic solution in an in vitro model of hypothermic cardiac arrest. J Thorac Cardiovasc Surg 1995, 110:1642-1648.
20. Korichneva I., Hoyos B., Chua R., Levi E., Hammerling U. Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. J Biol Chem 2002, 277:44327-44331.
21. Korichneva I. Zinc dynamics in the myocardial redox signaling network. Antioxid Redox Signal 2006, 8:1707-1721.
22. Palmiter R.D., Findley S.D. Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J 1995, 14:639-649.
23. Sensi S.L., Ton-That D., Weiss J.H. Mitochondrial sequestration and Ca(2+)-dependent release of cytosolic Zn(2+) loads in cortical neurons. Neurobiol Dis 2002, 10:100-108.
24. Atar D., Backx P.H., Appel M.M., Gao W.D., Marban E. Excitation-transcription coupling mediated by zinc influx through voltage-dependent calcium channels. J Biol Chem 1995, 270:2473-2477.
25. Ohana E., Segal D., Palty R., Ton-That D., Moran A., Sensi S.L., et al. A sodium zinc exchange mechanism is mediating extrusion of zinc in mammalian cells. J Biol Chem 2004, 279:4278-4284.
26. Maret W., Vallee B.L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A 1998, 95:3478-3482.
27. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83:456S-460S.
28. Finn A.V., Kramer M.C., Vorpahl M., Kolodgie F.D., Virmani R. Pharmacotherapy of coronary atherosclerosis. Expert Opin Pharmacother 2009, 10:1587-1603.
29. Nakashima Y., Fujii H., Sumiyoshi S., Wight T.N., Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007, 27:1159-1165.
30. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
31. Little P.J., Osman N., O'Brien K.D. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 2008, 19:448-454.
32. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
33. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996, 94:2013-2020.
34. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989, 2:941-944.
35. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976, 295:369-377.
36. Meerarani P., Reiterer G., Toborek M., Hennig B. Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. J Nutr 2003, 133:3058-3064.
37. Litwin M., Clark K., Noack L., Furze J., Berndt M., Albelda S., et al. Novel cytokine-independent induction of endothelial adhesion molecules regulated by platelet/endothelial cell adhesion molecule (CD31). J Cell Biol 1997, 139:219-228.
38. Newton A.C. Protein kinase C: structure, function, and regulation. J Biol Chem 1995, 270:28495-28498.
39. Ivey M.E., Little P.J. Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thromb Res 2008, 123:288-297.
40. Ballinger M.L., Ivey M.E., Osman N., Thomas W.G., Little P.J. Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL. Atherosclerosis 2009, 205:451-457.
41. Stadler N., Lindner R.A., Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004, 24:949-954.
42. Rancic Z., Radak D., Stojanovic D. [Early detection of asymptomatic carotid disease in patients with obliterative arteriosclerosis of the lower extremities]. Srp Arh Celok Lek 2002, 130:258-264.
43. Gorelik O., Almoznino-Sarafian D., Feder I., Wachsman O., Alon I., Litvinjuk V., et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 2003, 99:177-181.
44. Shokrzadeh M., Ghaemian A., Salehifar E., Aliakbari S., Saravi S.S., Ebrahimi P. Serum zinc and copper levels in ischemic cardiomyopathy. Biol Trace Elem Res 2009, 127:116-123.
45. Singh R.B., Niaz M.A., Rastogi S.S., Bajaj S., Gaoli Z., Shoumin Z. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. J Am Coll Nutr 1998, 17:564-570.
46. Witte K.K., Clark A.L., Cleland J.G. Chronic heart failure and micronutrients. J Am Coll Cardiol 2001, 37:1765-1774.
47. Etzion Y., Ganiel A., Beharier O., Shalev A., Novack V., Volvich L., et al. Correlation between atrial ZnT-1 expression and atrial fibrillation in humans: a pilot study. J Cardiovasc Electrophysiol 2008, 19:157-164.
48. Beharier O., Etzion Y., Katz A., Friedman H., Tenbosh N., Zacharish S., et al. Crosstalk between L-type calcium channels and ZnT-1, a new player in rate-dependent cardiac electrical remodeling. Cell Calcium 2007, 42:71-82.
49. Levy S., Beharier O., Etzion Y., Mor M., Buzaglo L., Shaltiel L., et al. Molecular basis for zinc transporter 1 action as an endogenous inhibitor of L-type calcium channels. J Biol Chem 2009, 284:32434-32443.
50. Poornima I.G., Parikh P., Shannon R.P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006, 98:596-605.
51. Hoyos B., Imam A., Korichneva I., Levi E., Chua R., Hammerling U. Activation of cRaf kinase by ultraviolet light: regulation by retinoids. J Biol Chem 2002, 277:23949-23957.
52. Korichneva I. Redox regulation of cardiac protein kinase C. J Exp Clin Cardiol 2005, 10:256-261.
53. Das Evcimen N., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007, 55:498-510.
54. Yaras N., Bilginoglu A., Vassort G., Turan B. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol 2007, 292:H912-H920.
55. Causmer A.B. Zinc, insulin and diabetes. J Am Coll Nutr 1998, 17:109-115.
56. Tayler C.G. Zinc, the pancreas, and diabetes: insights from rodent studies and future directions. Biometals 2005, 18:305-312.
57. Yoshikawa Y., Ueda E., Kawabe K., Miyake H., Takino T., Sakurai H., Kojima Y. Development of new insulinomimetic zinc (II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies. J Biol Inorg Chem 2002, 7:68-73.
58. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445(7130):881-885.
59. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.
60. Tang X., Shay N.F. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-L1 fibroblasts and adipocytes. J Nutr 2001, 131:1414-1420.
61. Haase H., Maret W. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals 2005, 18:333-338.
62. Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., Gustafson T.A., Kusari J. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 1997, 272:1639-1645.
63. Dadke S., Kusari A., Kusari J. Phosphorylation and activation of protein tyrosine phosphatase (PTP) 1B by insulin receptor. Mol Cell Biochem 2001, 221:147-154.
64. Kenner K.A., Anyanwu E., Olefsky J.M., Kusari J. Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J Biol Chem 1996, 271:19810-19816.
65. Ross S.A., Gulve E.A., Wang M. Chemistry and biochemistry of type 2 diabetes. Chem Rev 2004, 104:1255-1282.
66. Zabolotny J.M., Haj F.G., Kim Y.B., Kim H.J., Shulman G.I., Kim J.K., et al. Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 2004, 279:24844-24851.
67. Mahadev K., Zilbering A., Zhu L., Goldstein B.J. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem 2001, 276:21938-21942.
68. Krieger-Brauer H.I., Medda P.K., Kather H. Insulin-induced activation of NADPH-dependent H2O2 generation in human adipocyte plasma membranes is mediated by Galphai2. J Biol Chem 1997, 272:10135-10143.
69. Wang J., Song Y., Elsherif L., Song Z., Zhou G., Prabhu S.D., et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113:544-554.
70. Soinio M., Marniemi J., Laakso M., Pyorala K., Lehto S., Ronnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 2007, 30:523-528.
71. Cohen N., Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev 2006, 11:19-24.
72. Golik A., Cohen N., Ramot Y., Maor J., Moses R., Weissgarten J., et al. Type II diabetes mellitus, congestive heart failure, and zinc metabolism. Biol Trace Elem Res 1993, 39:171-175.
73. Trasobares E., Corbaton A., Gonzalez-Estecha M., Lopez-Colon J.L., Prats P., Olivan P., et al. Effects of angiotensin-converting enzyme inhibitors (ACE i) on zinc metabolism in patients with heart failure. J Trace Elem Med Biol 2007, 21(suppl 1):53-55.